Discover a groundbreaking webinar delving into the in vitro assays for proteolysis targeting chimera (PROTAC). PROTACs are being developed more and more for many kinds of target proteins, even for “undruggable targets.”
A PROTAC is a heterobifunctional molecule that utilizes the ubiquitin-proteasome system (UPS) to degrade a target protein. The simultaneous binding of the target protein and ligase by the PROTAC induces ubiquitylation of the target protein. Afterward, the target protein is subsequently degraded by the UPS. Then the PROTAC is recycled to target another target protein. This novel, catalytic-type mechanism of action is called “event-driven” pharmacology, which contrasts with “occupancy-driven” pharmacology, whereby the function of a target protein is directly blocked by a small-molecule inhibitor.
The ubiquitin-mediated destruction of cellular proteins plays a crucial part in many cellular functions by altering the cellular protein concentration. The discovery of specific proteins that are ubiquitylated before degradation in the 1970s led to the 2004 Nobel Prize in chemistry.
Since then, with the catalytically “event-driven” pharmacology, the potency of binding affinity to the target protein is no longer the key aspect of a PROTAC. However, more insights and better assays to help the structure-activity relationship (SAR) for PROTACs are needed.
Register for this webinar to explore in vitro assays for PROTAC and similar applications for molecular glues for targeted protein degradation (TPD).
Yuzhou Xu, MS, Senior Director, Biology and Pharmacology, Shanghai ChemPartner
Yuzhou Xu, MS, is a Senior Director in the biology and pharmacology department at Shanghai ChemPartner and has extensive experience in CRO drug development and focuses on in vitro biology to support early drug discovery.
Yuzhou Xu received his MS in Biochemical Engineering from East China University of Science and Technology and has significant expertise in assay development, including biochemical assays, enzymatic assays, cell-based functional assays and more. Additionally, he has extensive experience in enzymology and mechanism of action (MoA) research.
Who Should Attend?
This webinar will appeal to:
- Chemists, biologists, biochemists, etc. interested in drug discovery and development
- Those with a keen interest in targeting proteins
- Anyone interested in using PROTACs to advance drug discovery pipelines
What You Will Learn
Attendees will gain insights into:
- Novel proteolysis targeting chimeras (PROTAC) evaluation platform to support the structure-activity relationship (SAR) for PROTACs
- Similar application for molecular glues for targeted protein degradation (TPD)
- The future beyond TPD
Shanghai ChemPartner, which includes ChemPartner and ChemPartner Biologics, is a CRO/CDMO offering a broad range of drug discovery, development, and manufacturing services.
ChemPartner is a science-based, technology-driven global CRO and CDMO offering a broad range of services including discovery chemistry, biology, pharmacology, DMPK, and exploratory toxicology as well as biologics discovery, CMC development, and manufacturing.
ChemPartner serves a diverse global client base as more and more pharmaceutical and biotech companies look for alliance partners to provide intellectual contributions and exceptional technical expertise. With locations and representatives in China, Europe, and the US, ChemPartner is uniquely positioned to be a true biopharmaceutical alliance partner.